中国医药
中國醫藥
중국의약
CHINA MEDICINE
2013年
9期
1259-1261
,共3页
甲地孕酮%DCF方案%进展期胃癌%生活质量
甲地孕酮%DCF方案%進展期胃癌%生活質量
갑지잉동%DCF방안%진전기위암%생활질량
Medroxyprogesterone acetate%DCF regimen%Advanced gastric cancer%Quality of life
目的 探讨甲地孕酮联合5-氟尿嘧啶+顺铂+多西紫杉醇(DCF)方案化疗对改善进展期胃癌(AGC)患者生活质量的作用.方法 42例AGC患者完全随机分为单纯DCF方案化疗组(DCF组,16例)和甲地孕酮联合DCF方案化疗组(甲地孕酮联合DCF组,26例),患者均给予DCF方案化疗,其中甲地孕酮联合DCF组同时给予甲地孕酮口服治疗,化疗方案为28 d为1个周期,至少化疗2个周期.观察并记录患者治疗前后卡氏行为状态(KPS)评分、食欲、体重情况以及化疗毒副作用、全身情况变化.结果 诊疗后甲地孕酮联合DCF组有20例(76.9％)KPS评分提高,DCF组有4例(25.0％) KPS评分提高,2组差异有统计学学意(P＜0.05)；甲地孕酮联合DCF组食欲增加者21例(80.8％),DCF组食欲增加者3例(18.8％),组间差异有统计学意义(P＜0.05).甲地孕酮联合DCF组体重增加者19例(73.1％),DCF组体重增加者2例(12.5％),组间差异有统计学意义(P＜0.05).甲地孕酮联合DCF组出现Ⅱ度以上胃肠道反应5例(19.2％),DCF组出现Ⅱ度以上胃肠道反应11例(68.8％),组间差异有统计学意义(P＜0.05).甲地孕酮联合DCF组出现Ⅱ度以上白细胞计数减少6例(23.1％),DCF组出现Ⅱ度以上白细胞计数减少10例(62.5％),组间差异有统计学意义(P＜0.05).结论 甲地孕酮联合DCF方案治疗AGC,可减轻化疗所致消化道反应及骨髓毒性,改善患者的生活质量.
目的 探討甲地孕酮聯閤5-氟尿嘧啶+順鉑+多西紫杉醇(DCF)方案化療對改善進展期胃癌(AGC)患者生活質量的作用.方法 42例AGC患者完全隨機分為單純DCF方案化療組(DCF組,16例)和甲地孕酮聯閤DCF方案化療組(甲地孕酮聯閤DCF組,26例),患者均給予DCF方案化療,其中甲地孕酮聯閤DCF組同時給予甲地孕酮口服治療,化療方案為28 d為1箇週期,至少化療2箇週期.觀察併記錄患者治療前後卡氏行為狀態(KPS)評分、食欲、體重情況以及化療毒副作用、全身情況變化.結果 診療後甲地孕酮聯閤DCF組有20例(76.9％)KPS評分提高,DCF組有4例(25.0％) KPS評分提高,2組差異有統計學學意(P＜0.05)；甲地孕酮聯閤DCF組食欲增加者21例(80.8％),DCF組食欲增加者3例(18.8％),組間差異有統計學意義(P＜0.05).甲地孕酮聯閤DCF組體重增加者19例(73.1％),DCF組體重增加者2例(12.5％),組間差異有統計學意義(P＜0.05).甲地孕酮聯閤DCF組齣現Ⅱ度以上胃腸道反應5例(19.2％),DCF組齣現Ⅱ度以上胃腸道反應11例(68.8％),組間差異有統計學意義(P＜0.05).甲地孕酮聯閤DCF組齣現Ⅱ度以上白細胞計數減少6例(23.1％),DCF組齣現Ⅱ度以上白細胞計數減少10例(62.5％),組間差異有統計學意義(P＜0.05).結論 甲地孕酮聯閤DCF方案治療AGC,可減輕化療所緻消化道反應及骨髓毒性,改善患者的生活質量.
목적 탐토갑지잉동연합5-불뇨밀정+순박+다서자삼순(DCF)방안화료대개선진전기위암(AGC)환자생활질량적작용.방법 42례AGC환자완전수궤분위단순DCF방안화료조(DCF조,16례)화갑지잉동연합DCF방안화료조(갑지잉동연합DCF조,26례),환자균급여DCF방안화료,기중갑지잉동연합DCF조동시급여갑지잉동구복치료,화료방안위28 d위1개주기,지소화료2개주기.관찰병기록환자치료전후잡씨행위상태(KPS)평분、식욕、체중정황이급화료독부작용、전신정황변화.결과 진료후갑지잉동연합DCF조유20례(76.9％)KPS평분제고,DCF조유4례(25.0％) KPS평분제고,2조차이유통계학학의(P＜0.05)；갑지잉동연합DCF조식욕증가자21례(80.8％),DCF조식욕증가자3례(18.8％),조간차이유통계학의의(P＜0.05).갑지잉동연합DCF조체중증가자19례(73.1％),DCF조체중증가자2례(12.5％),조간차이유통계학의의(P＜0.05).갑지잉동연합DCF조출현Ⅱ도이상위장도반응5례(19.2％),DCF조출현Ⅱ도이상위장도반응11례(68.8％),조간차이유통계학의의(P＜0.05).갑지잉동연합DCF조출현Ⅱ도이상백세포계수감소6례(23.1％),DCF조출현Ⅱ도이상백세포계수감소10례(62.5％),조간차이유통계학의의(P＜0.05).결론 갑지잉동연합DCF방안치료AGC,가감경화료소치소화도반응급골수독성,개선환자적생활질량.
Objective To observe the effect of medroxyprogesterone acetate (MPA) combined with DCF (docetaxel,cisplatin,fluorouracil)regimen chemotherapy on improving life quality of patients with advanced gastric cancer (AGC).Methods All 42 cases with AGC were randomly divided into DCF group treated only by chemotherapy,and MPA combined with DCF group treated only by MPA combined with chemotherapy.The change of Karnofsky performance status (KPS),appetite,body weight toxicum reaction and the whole body change of two groups were observed.Results Of 42 cases,20 cases (76.9％) improved on KPS in MPA combined with DCF group and 4 cases (25.0％) improved in DCF group,the difference between the two groups were statistically significant (P＜0.05) ; 21 cases (80.8％) had an increase on appetite and 19 cases (73.1％) had an increase on weight in MPA combined with DCF group,while the numbers in DCF group were 3 cases (18.8％) and 2 cases (12.5％) respectively,the difference between the two groups were statistically significant (P ＜ 0.05) ; 5 cases (19.2％) had grade Ⅱ or more gastrointestinal reaction in MPA combined with DCF group and 11 cases (68.8％)in DCF group,6 cases (23.1％) had grade Ⅱ] or more leucopenia in MPA combined with DCF group and 10 cases (62.5) in DCF group,the difference between the two groups were statistically significant (P ＜0.05).Conclusion MPA combined with DCF regimen chemotherapy can reduce gastrointestinal side effects and hematologic toxicities,increase appetite and improve life quality in patients with AGC.
